Pricing Log in Create free account
Saturday 7 November 2026 Export NRIX’s income statement to Excel — free account

Nurix Therapeutics, Inc.

NRIX Healthcare Biotechnology

Nurix Therapeutics, Inc.’s revenue for fiscal 2025 (year ended November 2025) was $84.0 million, up 54.0% from fiscal 2024.

Revenue
+8,426.3%
EPS
+578.6%
Free cash flow
+1,122.1%

Quarter to August 2026, against a year earlier

15.30 0.46 +3.10%
Market cap
$1.6B
P/E
6.1×
Fwd P/E
5.5×
Dividend yield
—
F-score
4/9
Altman Z
3.77
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 5.20
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 1 4 1 1 4 3 3 4 4 2 6 2
Insider Ownership 6.73%

Capital & Financial Ratios $m

Size
Market Cap 1,620.00
Revenue ttm 701.94
Net income ttm 294.88
Free cash flow ttm 369.81
Net debt Q (1,048.25)
Valuation
P/E 6.06
Forward P/E 5.51
Price / sales 2.42
Forward P/S Powerpack
Price / FCF 4.59
Price / book 1.75
Financial health
Current ratio Q 8.44 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (13.21)
Growth
Revenue growth Q +8,426.27% (above 0%: growing)
Operating income growth Q +712.19% (above 0%: growing)
EPS, this year +177.12% (at or above 15%: strong)
EPS, next year A −190.94% (below 0%: weak)
Revenue, next year A +786.88% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +32.31% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.9×, against a ten-year median of 9.2×; over the ten years it ranged from 0.7× in 2023 to 61.2× in 2026.
P/S against its own 10 years 0.13%
10-year low 10-year high
P/B against its own 10 years 11.64%
10-year low 10-year high
EV/Sales against its own 10 years 1.03%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 288 610 593 1,048
Receivables — — — 20
Inventory — — — —
Other — — — —
296 619 607 1,104
2023 2024 2025 Q'26
Payables 6 11 11 33
ST’ Debt — — — —
Other — — — 22
87 96 86 131

Compound Annual Growth %

10y 5y 3y
Sales — 36.35% 29.55%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 13.17% 21.05%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.56 Actual 4.73

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.84 −0.82 Beat by 0.02
Q1 FY26 −0.76 −0.79 Miss by 0.03
Q2 FY26 −0.73 −0.81 Miss by 0.08
Q3 FY26 −0.56 4.73 Beat by 5.29
Q4 FY26 −0.46 — Reports 27 January 2027

EPS $

Feb May Aug Nov Year
’26 (0.79) (0.81) 4.73 — —
’25 (0.67) (0.52) (1.03) (0.82) (3.05)
’24 (0.76) (0.71) (0.67) (0.75) (2.88)
’23 (0.75) (0.45) (0.68) (0.77) (2.65)
’22 (0.95) (1.01) (0.90) (0.87) (3.71)
’21 (0.63) (0.60) (0.65) (0.85) (2.73)
’20 (3.50) 1.54 (1.09) (0.51) (2.76)
Fiscal quarters ending in the months shown.

Revenue $m

Feb May Aug Nov Year
’26 6 9 673 — —
’25 18 44 8 14 84
’24 17 12 13 13 55
’23 13 31 18 15 77
’22 10 11 11 7 39
’21 5 7 10 7 30
’20 3 4 4 7 18
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Feb May Aug Nov Year
’26 (72) (97) 616 — —
’25 (61) (63) (57) (68) (249)
’24 (42) (40) (42) (49) (173)
’23 (48) (18) (41) 27 (81)
’22 (43) (33) (46) (38) (160)
’21 8 (32) (30) (31) (84)
’20 41 (14) (6) (20) 0
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Feb May Aug Nov Year
’26 (73) (99) 614 — —
’25 (65) (66) (60) (73) (263)
’24 (45) (42) (45) (51) (182)
’23 (51) (20) (44) 24 (90)
’22 (46) (36) (50) (41) (172)
’21 7 (34) (32) (32) (90)
’20 41 (16) (8) (21) (5)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to November

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Aug ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — 37 31 18 30 39 77 55 84 702 +12.2% 745 123 318 +55.9%
Gross margin, % — — 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 0.0 pt
EBT — — (9) (21) (64) (117) (180) (144) (193) (264) 308 +62.2%
EBT margin, % — — (23.82) (68.97) (357.90) (393.49) (466.93) (186.98) (354.36) (314.00) 43.91 (290.2) pt
Net income — 0 (9) (22) (43) (117) (180) (144) (194) (264) 295 n/m
Per share, $
Per share, $ Revenue — — 13.29 9.45 1.14 0.69 0.79 1.42 0.81 0.97 6.29 (31.2%)
Earnings — — (3.35) (6.59) (2.76) (2.73) (3.71) (2.65) (2.88) (3.05) 2.51 (1.3%)
Cash flow — — (11.24) 0.18 (0.01) (1.97) (3.29) (1.50) (2.57) (2.88) 3.40 (17.7%)
Capex — — (0.56) (0.50) (0.29) (0.13) (0.25) (0.15) (0.14) (0.16) (0.09) (16.4%)
Free cash flow — — (11.81) (0.32) (0.30) (2.10) (3.54) (1.65) (2.71) (3.04) 3.31 (17.6%)
Book value — — (13.08) (17.53) 18.52 7.98 6.25 3.69 7.85 6.22 8.68 n/m
Shares, m — — 3 3 16 43 49 54 67 87 105 +63.1%
Valuation, ×
Valuation, × P/E — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.06 0.0
P/S — — 0.00 0.00 37.49 41.55 15.59 4.39 26.44 17.45 2.42 17.9
P/B — — 0.00 0.00 2.30 3.61 1.98 1.69 2.74 2.72 1.75 1.9
EV/Sales — — 0.00 0.00 21.71 31.61 7.59 0.65 15.27 10.39 0.92 10.9
EV/FCF — — (2.19) (2.19) (83.50) (10.45) (1.70) (0.56) (4.58) (3.31) 1.75 (13.6)
Cash, $m
Cash, $m Operating cash flow — — (32) 1 0 (84) (160) (81) (173) (249) 379 +34.3%
Capex — — (2) (2) (5) (6) (12) (8) (9) (14) (10) +36.5%
Free cash flow — — (33) (1) (5) (90) (172) (90) (182) (263) 370 +34.4%
Balance, $m
Balance, $m Working capital — — 8 23 254 245 248 209 524 520 973 +82.1%
Net debt — — (39) (38) (281) (296) (309) (288) (610) (593) (1,048) +47.5%
Shareholders’ equity — — (37) (58) 290 342 304 200 527 539 968 n/m
Returns, %
Returns, % ROA — — (41.54) (48.52) (19.64) (26.85) (40.37) (37.27) (37.77) (38.96) 34.33 +2.6 pt
ROIC — — 0.00 0.00 (445.28) (158.17) 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE — — 19.94 45.89 (37.19) (37.05) (55.84) (57.10) (53.22) (49.63) 43.99 (69.6) pt
People
People Employees — — — 103 135 242 297 284 286 317 — +20.6%
Revenue/emp, $m — — 0.00 0.30 0.13 0.12 0.13 0.27 0.19 0.26 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Nov 2025 · latest quarter Aug 2026 · fundamentals updated 2 Nov 2026

Nurix Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
LYCA Lycia Therapeutics Inc. $1.7B — — — — — — — Compare
NRIX Nurix Therapeutics, Inc. $1.6B 6.1× 5.5× +8,426.27% (above 0%: growing) n/m +1,122.10% (above 0%: growing) 100.00% 83.12%
ABSI Absci Corporation $1.6B — (loss-making) — (loss-making) −46.37% (below 0%: shrinking) n/m −71.74% (below 0%: shrinking) 100.00% (10,741.51%) Compare
GENB Generate Biomedicines, Inc. $1.6B — (loss-making) — (loss-making) — n/m −224.24% (below 0%: shrinking) 100.00% (1,134.21%) Compare
NVAX Novavax, Inc. $1.6B — (loss-making) 110× −3.05% (below 0%: shrinking) n/m −189.09% (below 0%: shrinking) 65.61% (45.80%) Compare
SLS SELLAS Life Sciences Group, Inc. $1.6B — (loss-making) — (loss-making) −57.10% (below 0%: shrinking) n/m −3.52% (below 0%: shrinking) 0.00% 0.00% Compare
KLRA Kailera Therapeutics, Inc. $1.6B — (loss-making) — — n/m −325.95% (below 0%: shrinking) — 0.00% Compare
BRVE Braveheart Bio, Inc. $1.6B — — — n/m — — 0.00% Compare
NTLA Intellia Therapeutics, Inc. $1.6B — (loss-making) — (loss-making) −48.03% (below 0%: shrinking) n/m −11.05% (below 0%: shrinking) 100.00% (1,707.73%) Compare
Median of peers $1.6B — — −47.20% — −130.41% 100.00% (45.80%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 27 March 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 6.37m (1.07m) 61.35
2024 5.81m 23.31m 76.72
2023 4.36m (913.89k) 21.58
2022 9.42m (5.02m) 42.99

Ownership

Directors and executive officers, together 6.70%
Baker Bros. Advisors LP 7.10%
Redmile Group, LLC 6.60%
BlackRock, Inc. 6.10%
Deep Track Capital, LP 5.30%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Nurix Therapeutics, Inc. (NRIX) Latest News

7 Nov

Impact 3 · · Simply Wall St.

4 Nov

Impact 4 · · InvestorsHub
Impact 3 · · Stocktwits

3 Nov

Impact 3 · · Stocktwits
Impact 3 · · Investing.com

22 Oct

Impact 3 · · Simply Wall St.

12 Oct

Impact 4 · · Investing.com
Impact 4 · · GlobeNewswire
Impact 3 · · Zacks

7 Oct

Impact 4 · · Simply Wall St.
Impact 4 · · GlobeNewswire

5 Oct

Impact 4 · · GlobeNewswire

29 Sep

Impact 4 ·

10 Sep

Impact 3 ·

9 Sep

Impact 3 ·

10 Aug

Impact 3 ·

5 Aug

Impact 4 ·

4 Aug

Impact 4 ·
Impact 3 ·

24 Jul

Impact 3 ·

21 Jul

Impact 5 ·

9 Jul

Impact 3 ·
Impact 3 ·

1 Jul

Impact 3 ·

30 Jun

Impact 4 ·

26 Jun

Impact 4 ·

25 Jun

Impact 4 · · Insider Monkey

16 Jun

Impact 3 ·

11 Jun

Impact 4 ·

8 Jun

Impact 4 ·
stockrow.com/NRIX · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com